Pasithea Therapeutics(KTTA.US)董事增持3万股普通股股份,价值约为1.29万美元

The director of Pasithea Therapeutics (KTTA.US) increased his shares of common stock by 30,000, worth about $12,900

Futu News ·  06/07/2023 09:38

On June 7, it was reported that according to the documents disclosed by the US Securities and Exchange Commission (SEC) on June 6,$Pasithea Therapeutics (KTTA.US)$Director STEINMAN LAWRENCE increased his holdings of common stock by 30,000 shares at an average price of $0.431 per share on June 2, worth about $12,900.


What is a statement of change in shareholding?

The SEC requires insiders of listed companies to publicly disclose their securities transactions and shareholding. When an insider's shareholding changes, depending on different circumstances, it is necessary to submit a statement of change in shareholding to the SEC within a certain period of time after the transaction is completed.

Insiders include the company's directors and executives, as well as any shareholder who owns 10% or more of the company's tradable shares.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment